# APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Source: https://onco.cc/trials/nct03175224/  
OnCo record `nct03175224` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Vebreltinib in metastatic cancer and thyroid cancer, run by Apollomics Inc., now recruiting.

## Summary

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors is a phase 2 interventional study registered as NCT03175224 by Apollomics Inc., with 497 participants planned, started 2017-09-27 and due to reach its primary completion in 2026-03-30. Interventions recorded: APL-101 Oral Capsules. Conditions listed: Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03175224
- Phase: 2
- Setting: Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- Sponsor: Apollomics Inc.
- Enrolled: 497

## Sources

- ClinicalTrials.gov NCT03175224: https://clinicaltrials.gov/study/NCT03175224

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- drugs: [Vebreltinib](https://onco.cc/drugs/vebreltinib/)
- companies: [Apollomics](https://onco.cc/companies/apollomics/)

---
JSON: https://onco.cc/api/v1/entities/nct03175224.json